Beta-Blockers for Migraine Prevention

First-Line Beta-Blockers

The American Heart Association recommends propranolol (80-240 mg daily) and timolol (20-30 mg daily) as first-line beta-blockers for migraine prevention, with strong evidence supporting their efficacy 1, 3, 4
The American Academy of Family Physicians suggests that metoprolol (100-200 mg daily) also has good evidence for migraine prevention and is commonly used off-label 1
Beta-blockers reduce migraine frequency, severity, and associated symptoms, improving quality of life, according to the American College of Physicians 2
The American Family Physician guidelines state that beta-blockers without intrinsic sympathomimetic activity are effective, while those with ISA are ineffective for migraine prevention 3, 5

The American Heart Association notes that atenolol and nadolol have limited but positive evidence for moderate effectiveness in migraine prevention 1
The American Family Physician guidelines mention that calcium channel blockers, such as verapamil, have moderate evidence for efficacy, though less consistent than beta-blockers 3, 5

The American College of Cardiology recommends considering beta-blockers as first-line therapy when treating a patient with both hypertension and migraine 1, 6
The American Family Physician guidelines suggest avoiding beta-blockers with intrinsic sympathomimetic activity as they are ineffective for migraine prevention 3
The Journal of the American College of Cardiology advises avoiding atenolol for hypertension management as it is less effective than placebo in reducing cardiovascular events, despite some efficacy in migraine 7

The American Family Physician guidelines state that common side effects of beta-blockers include fatigue, dizziness, nausea, depression, and insomnia, but these are generally well-tolerated 3
The American College of Physicians recommends using beta-blockers cautiously in patients with asthma, diabetes, or peripheral vascular disease 2
The American Family Physician guidelines suggest starting with low doses and titrating gradually to minimize side effects while achieving therapeutic benefits 4

The American Family Physician guidelines note that an adequate trial requires 2-3 months to determine efficacy, as benefits may not be immediately apparent 4, 6
The American Family Physician guidelines recommend considering tapering to find the minimum effective dose or discontinue after 6-12 months of successful treatment 4
The American College of Physicians suggests that prophylactic treatment is indicated for patients with two or more migraine attacks per month, attacks producing disability for three or more days per month, or use of acute medications more than twice weekly 2